Champions Oncology has entered into biotech deals with Teva Pharmaceuticals for drug discovery and development in oncology.
Champions Oncology announced the biotech deals resulting in the signing of a new discovery and drug development partnership with Teva Pharmaceutical which will utilize Champions TumorGraft technology platform to enhance and accelerate the clinical development of several of Teva's oncology compounds.
The biotech deals, using the Champions TumorGraft technology platform, aims to identify highly responsive cancer subtypes, and their corresponding molecular and biochemical biomarkers of responsiveness to Teva's novel therapeutic agents, hopefully leading to new and personalized therapeutic options for patients with cancer.
Under the terms of the biotech deals, Teva will pay Champions an upfront fee and Champions may also receive milestone payments and royalties for the compounds being studied if the response hypotheses are successfully utilized for clinical trial design and resulting commercial success of the compounds.
Report: Partnering Deals and Alliances with Teva
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity